Indo-Bangla Pharmaceuticals Limited reported unaudited earnings results for the third quarter and nine months ended on September 30, 2018. For the quarter, the company reported profit after tax of BDT 25.64 million and basic EPS of BDT 0.35 for the three months period ended on 31 March 2018 against profit after tax of BDT 22.94 million and basic EPS of BDT 0.31 for the same period of the previous year. However, Post-IPO basic EPS for the three months period ended on 31 March 2018 would be BDT 0.28. For the nine months, the company reported profit after tax of BDT 74.35 million and basic EPS of BDT 1.02 against profit after tax of BDT 73.99 million and basic EPS of BDT 1.01 for the same period of the previous year. However, Post-IPO EPS would be BDT 0.80 for nine months period ended on 31 March 2018. NAV per share (considering Pre-IPO paid up shares) would be BDT 13.86 as on 31 March 2018 and the same would be BDT 13.03 (considering Post-IPO paid up shares).